Abstract Number: 2247 • 2019 ACR/ARP Annual Meeting
Patient Factors Associated with Willingness to Change Rheumatoid Arthritis Medications
Background/Purpose: Evidence-based guidelines recommend escalation of therapy in patients with rheumatoid arthritis (RA) with inadequately controlled disease. However, some patients are hesitant to change therapies…Abstract Number: 2768 • 2019 ACR/ARP Annual Meeting
Changes in B Cell Profile as a Marker of Clinical Remission to TNF Inhibitors in Patients with Rheumatoid Arthritis
Background/Purpose: According to the EULAR recommendations, the therapeutic objective in patients with rheumatoid arthritis (RA) should be remission. Biological therapies, as TNF inhibitors (TNFi), have…Abstract Number: 35 • 2019 ACR/ARP Annual Meeting
Mass Cytometry Identifies Enhanced Histone H3 Citrullination and TNFα Production by CD14 Monocytes in Subjects At-Risk for Future Development of Rheumatoid Arthritis
Background/Purpose: Our group previously demonstrated that sputum neutrophils from subjects At-Risk for future rheumatoid arthritis (RA) spontaneously form neutrophil extracellular traps with elevated histone H3…Abstract Number: 515 • 2019 ACR/ARP Annual Meeting
Clinical Responses in Patients with Inadequate Response to bDMARDs upon Treatment with Upadacitinib
Background/Purpose: Upadacitinib (UPA), a JAK1-selective inhibitor, demonstrated efficacy in the SELECT-BEYOND study in patients (pts) with moderate to severe rheumatoid arthritis (RA) on a stable…Abstract Number: 848 • 2019 ACR/ARP Annual Meeting
Risk of Serious Infection with Long-Term Use of Low-Dose Glucocorticoids in Patients with Rheumatoid Arthritis
Background/Purpose: As many as 30-40% of patients with RA remain on long term glucocorticoids. Infection risk with higher dose glucocorticoids is well known, but evidence…Abstract Number: 1138 • 2019 ACR/ARP Annual Meeting
Outpatient Costs and Evaluation and Management (E&M) Expenditure Trends in Rheumatoid Arthritis (RA) Patients Treated with Biologic Therapies in US Community Practices
Background/Purpose: RA is an autoimmune disease affecting over 1.5 million Americans. Biologic disease-modifying antirheumatic drugs (bDMARDs) expanded treatment choices for RA patients (pts) in the…Abstract Number: 1770 • 2019 ACR/ARP Annual Meeting
Experimental Rheumatoid Joint Ameliorated by CRISPR Interference Targeting Long Non-coding RNA H19 Through Wnt Signaling Inactivation
Background/Purpose: Long non-coding RNAs (lncRNAs) participate in the rheumatoid arthritis (RA) pathogenesis. The aim of this study was to examine the lncRNA H19 and HOTAIR…Abstract Number: 2249 • 2019 ACR/ARP Annual Meeting
Evaluation of Rheumatoid Arthritis Patients’ Preferences Using Discrete Choice Experiment
Background/Purpose: Rheumatoid arthritis (RA) exerts multifaceted burden through medical expenditures, productivity losses, disability, and intangible costs of pain, fatigue, and loss of functional capacity. Patient…Abstract Number: 2771 • 2019 ACR/ARP Annual Meeting
A Phase I, Randomized, Double-blind, Placebo-controlled, Single Center, Single-dose Escalation to Investigate the Safety, Tolerability, and Pharmacodynamics of Subcutaneously Administered DEN-181 in Adult Patients with ACPA+ Rheumatoid Arthritis on Stable Methotrexate
Background/Purpose: Antigen-specific immunological tolerance strategies leverage the natural process of antigen presentation by dendritic cells (DCs) to regulate pathogenic T cells and B cells. We…Abstract Number: 38 • 2019 ACR/ARP Annual Meeting
Autophagy Receptor Optineurin in Synovial Fibroblasts Plays a Protective Role Against Joint Destruction in Rheumatoid Arthritis
Background/Purpose: Joint destructions progress throughout the course of rheumatoid arthritis (RA) without complete remission. Optineurin (OPTN) is an autophagy receptor with multiple functions related to…Abstract Number: 517 • 2019 ACR/ARP Annual Meeting
A Subgroup Analysis of Clinical Efficacy Response and Quality of Life Outcomes from Phase 3 Study of Filgotinib in Patients with Inadequate Response to Biologic DMARDs
Background/Purpose: There is an unmet medical need to treat RA in patients who have failed prior biologic DMARD treatments (biologic DMARD inadequate response; bDMARD-IR), some…Abstract Number: 928 • 2019 ACR/ARP Annual Meeting
Monotherapy with Upadacitinib in MTX-naïve Patients with Rheumatoid Arthritis: Results at 48 Weeks
Background/Purpose: Upadacitinib (UPA), a JAK1-selective inhibitor, was efficacious as monotherapy upto 24 weeks (wks) in MTX-naive patients (pts) with active RA.1 To assess safety and efficacy…Abstract Number: 1332 • 2019 ACR/ARP Annual Meeting
United States Rheumatology Practice-Based Real-World Evidence of Infusion Reactions in Rheumatoid Arthritis Patients Treated with Intravenous Golimumab or Infliximab: Impact of Prior Biologic Exposure and Methotrexate Utilization
Background/Purpose: AWARE (Comparative and Pragmatic Study of Golimumab IV Versus Infliximab in Rheumatoid Arthritis) is an ongoing Phase 4 comparator study designed to provide a…Abstract Number: 1772 • 2019 ACR/ARP Annual Meeting
Chronotherapy Using Baricitinib Attenuates Collagen-induced Arthritis in Mice
Background/Purpose: Diurnal variations are observed in symptoms of rheumatoid arthritis (RA). Among them, “morning stiffness of joints” is closely reflects the daily medical condition of…Abstract Number: 2279 • 2019 ACR/ARP Annual Meeting
Pregnancy in Rheumatoid Arthritis: Continue, Reduce or Stop TNF Inhibitors? A Prospective Observational Study
Background/Purpose: Women with active Rheumatoid Arthritis (RA) are more prone to relapses and complications during pregnancy. The potential risks of disease activation and treatment during…
- « Previous Page
- 1
- …
- 163
- 164
- 165
- 166
- 167
- …
- 188
- Next Page »